Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus

American Journal of Physiology. Endocrinology and Metabolism
Emanuel R ChristDavid L Russell-Jones

Abstract

Abnormal lipid metabolism may be related to the increased cardiovascular risk in type 1 diabetes. Secretion and clearance rates of very low density lipoprotein (VLDL) apolipoprotein B100 (apoB) determine plasma lipid concentrations. Type 1 diabetes is characterized by increased growth hormone (GH) secretion and decreased insulin-like growth factor (IGF) I concentrations. High-dose IGF-I therapy improves the lipid profile in type 1 diabetes. This study examined the effect of low-dose (40 microg.kg(-1).day(-1)) IGF-I therapy on VLDL apoB metabolism, VLDL composition, and the GH-IGF-I axis during euglycemia in type 1 diabetes. Using a stable isotope technique, VLDL apoB kinetics were estimated before and after 1 wk of IGF-I therapy in 12 patients with type 1 diabetes in a double-blind, placebo-controlled trial. Fasting plasma triglyceride (P < 0.03), VLDL-triglyceride concentrations (P < 0.05), and the VLDL-triglyceride-to-VLDL apoB ratio (P < 0.002) significantly decreased after IGF-I therapy, whereas VLDL apoB kinetics were not significantly affected by IGF-I therapy. IGF-I therapy resulted in a significant increase in IGF-I and a significant reduction in GH concentrations. The mean overnight insulin concentrations during euglyc...Continue Reading

References

Dec 1, 1992·The Journal of Clinical Investigation·P D ZenobiE R Froesch
Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M RudlingB Angelin
Oct 1, 1992·Diabetes·F L Dunn
Jun 1, 1992·The Journal of Clinical Investigation·P D ZenobiE R Froesch
Jun 1, 1991·The American Journal of Physiology·M Böni-SchnetzlerE R Froesch
Jun 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·A Flyvbjerg
May 15, 1990·The Biochemical Journal·G F Gibbons
Apr 1, 1989·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·A MøllerJ S Christiansen
Jun 1, 1994·Current Opinion in Lipidology·B Angelin, M Rudling
May 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A D Sniderman, K Cianflone
May 1, 1996·The Diabetes Educator·L S Jordan
Jan 23, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·C J Packard, J Shepherd
Mar 4, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·J A JanssenS W Lamberts
Apr 1, 1959·Physiological Reviews·M I GREGERSEN, R A RAWSON

❮ Previous
Next ❯

Citations

Apr 17, 2009·Pituitary·José Alexandre Curiacos de Almeida LemeEliete Luciano
Feb 10, 2009·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·J A C A LemeE Luciano
Jun 5, 2003·Circulation·Marcel T B TwicklerHans P F Koppeschaar
Sep 30, 2021·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Vanessa Y TanNicholas J Timpson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.